Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?
One reason for the inadequacy of current renoprotective therapy and the persistent poor renal prognosis in diabetic nephropathy is the large interindividual variation in response to treatment. Genetic as well as non-genetic factors are known to influence treatment efficacy. This Commentary summarizes the impact of the angiotensin-converting enzyme (ACE) insertion/deletion polymorphism in the ACE gene on initiation and progression of diabetic nephropathy.
Jacobsen
P K
PK
Steno Diabetes Center, Gentofte, Denmark. pkjacobsen@dadlnet.dk
Tarnow
L
L
Parving
H-H
HH
D000483:Alleles; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D044466:Asian People; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D017353:Gene Deletion; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D016254:Mutagenesis, Insertional; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis; D016019:Survival Analysis
D000806:Angiotensin-Converting Enzyme Inhibitors; D007703:Peptidyl-Dipeptidase A